The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
Open accessAbstract
OBJECTIVE: To investigate pharmacokinetic and pharmacodynamic factors associated with population differences in warfarin doses needed to achieve anticoagulation, in particular the possible involvement of genetic variability in vitamin K epoxide reductase (VKOR) and CYP2C9. METHODS: Warfarin maintenance dose, unbound plasma S-warfarin concentration [Cu(S)] and INR were determined in 157 Caucasians, 172 Japanese, and 36 African-Americans stably anticoagulated patients. In a subset (n = 166), fully carboxylated plasma normal prothrombin levels (NPT) were also measured. Genotyping for seven CYP2C9 (CYP2C9*1 through 6 and *11) and seven VKORC1 variants were performed in 115 Caucasians and 64 Japanese patients and 66 healthy African-Americans. Multivariate analysis was performed to identify covariates associated with warfarin requirement. RESULTS: The relationship between NPT and Cu(S) indicated Japanese are more susceptible to inhibition of NPT production by S-warfarin than the other two populations. VKORC1 1173 C > T had a greater frequency in Japanese (89.1%) than Caucasians (42.2%) and African-Americans (8.6%). CYP2C9 variants with reduced metabolizing ability were less frequent in Japanese compared to the other two populations. The median warfarin dose was significantly higher in Caucasians than Japanese patients (5.5 versus 3.5 mg/day), however, when matched for CYP2C9*1 homozygosity, no difference in dose was observed between VKORC1 genotype-matched groups. Furthermore, VKORC1 1173C > T and CYP2C9 (*2/*3/*11) genotypes, age and weight were identified as independent covariates contributing to interpatient variability in warfarin dosage. CONCLUSIONS: Both VKORC1 and CYP2C9 polymorphisms contribute to inter-population difference in warfarin doses among the three populations, but their contribution to intra-population variability may differ within each population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Due to genetic differences in pharmacokinetics and pharmacodynamics, clopidogrel [29], phenytoin [30], warfarin [31], clozapine [32], and carbamazepine [33] also had variable efficacy and side-effect profiles in Western and non-Western individuals.”
From Hasty generalizations and generics in medical research: A systematic review (2024) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H. I., Jacobson, A. K., & Hylek, E. M. (2004) · CHEST Journal · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,530
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,391
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,239
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Rost, S., Fregin, A., Ivaškevičius, V., Conzelmann, E., Hörtnagel, K., Pelz, H., Lappegård, K. T., Seifried, E., Scharrer, I., Tuddenham, E. G. D., et al. (2004) · Nature · doi:10.1038/nature02214 · Cited by 1,152
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,052
D’Andrea, G., D’Ambrosio, R., Perna, P. D., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E., & Margaglione, M. (2004) · Blood · doi:10.1182/blood-2004-06-2111 · Cited by 696
Yuan, H., Chen, J., Lee, M. T. M., Wung, J., Chen, Y., Charng, M., Lu, M.-J., Hung, C., Wei, C.-Y., Chen, C.-H., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi180 · Cited by 484
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S. E., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D. R., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500313 · Cited by 462
Bodin, L. (2005) · Blood · doi:10.1182/blood-2005-01-0341 · Cited by 360
Scordo, M. G. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129321 · Cited by 344
Self-citation
Cited by
Sorted by citations
Items 201–300 of 374
CYP2C9 polymorphism studies in the Saudi population
Saour, J., Shereen, A. W., Saour, B. J., & Mammo, L. A. (2011) · Saudi Medical Journal · doi:10.15537/1658-3175.5268 · Cited by 12
Current strategies in prophylaxis and treatment of venous thromboembolism
Schulman, S. (2008) · Annals of Medicine · doi:10.1080/07853890802010717 · Cited by 11
Warfarin maintenance dose adjustment with indirect pharmacodynamic model in rats
Cao, Y., Liu, X., Chen, Y., Hao, K., & Wang, G. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.10.009 · Cited by 12
Hasty generalizations and generics in medical research: A systematic review
Peters, U., Sherling, H. R., & Chin-Yee, B. (2024) · PLOS ONE · doi:10.1371/journal.pone.0306749 · Cited by 11
Ambe, K., Akita, A., Wei, J., Yoshii, Y., Onishi, M., & Tohkin, M. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2881 · Cited by 12
Mlynarsky, L., Bejarano‐Achache, I., Muszkat, M., & Caraco, Y. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1143-z · Cited by 11
Mansouri, K., Hoseinkhani, Z., Sadeghalvad, M., Norooznezhad, F., Khodarahmi, R., Fazilati, M., Mahnam, A., & Fattahi, A. (2018) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.235165 · Cited by 11
Hiraide, M., Minowa, Y., Nakano, Y., Suzuki, K., Shiga, T., Nishio, M., Miyoshi, J., Takahashi, H., & Hama, T. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218801061 · Cited by 11
Self-citationPharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants
Perini, J. A., Vargens, D. D., Santana, I. L. S., Moriguchi, E. H., Ribeiro‐dos‐Santos, Â., Tsutsumi, M. Y., & Suarez‐Kurtz, G. (2009) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2009001200010 · Cited by 11
How does race and ethnicity effect the precision treatment of asthma?
Zhang, E., Levin, A. M., & Williams, L. K. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1690396 · Cited by 11
Krajčíová, Ľ., Deziova, L., Petrovič, R., Luha, J., Turčáni, P., & Chandoga, J. (2014) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2014_109 · Cited by 10
Tsuruoka, N., Iwakiri, R., Sakata, Y., Fujimoto, K., Kamiya, T., Joh, T., Tokunaga, K., Takahashi, S., Kinoshita, Y., Uchiyama, K., et al. (2018) · Digestion · doi:10.1159/000484228 · Cited by 10
Sun, B., Wen, Y., Culhane‐Pera, K. A., Lo, M., Xiong, T., Lee, K., Peng, K., Thyagarajan, B., Bishop, J. R., Zierhut, H. A., et al. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2487 · Cited by 10
Pitfall of genome-wide association studies: Sources of inconsistency in genotypes and their effects
Hong, H., Xu, L., Su, Z., Liu, J., Ge, W., Shen, J., Fang, H., Perkins, R., Shi, L. M., & Tong, W. (2012) · Journal of Biomedical Science and Engineering · doi:10.4236/jbise.2012.510069 · Cited by 9
Krajčíová, Ľ., Petrovič, R., Déžiová, Ľ., Chandoga, J., & Turčáni, P. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12348 · Cited by 9
Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers
Verma, I., Nahar, R., Saxena, R., & Deb, R. (2012) · Indian journal of human genetics · doi:10.4103/0971-6866.107987 · Cited by 8
The Population Attributable Fraction as a Measure of the Impact of Warfarin Pharmacogenetic Testing
Chan, S. L., Suo, C., Chia, K. S., & Teo, Y. Y. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.104 · Cited by 8
Allele Frequency and Genotype Distribution of 9 SNPs in the Kazakh Population
Romanova, A. A. (2014) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000129 · Cited by 8
Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
Gao, L., He, L., Luo, J. J., Xu, B., Yang, J., Zhang, Y., Yang, T., Li, K., Tian, J., Wang, H.-J., et al. (2011) · PubMed · Cited by 8
Li, W., Bu, F., Li, R., Wang, B., Shaikh, A. S., Zhang, Y., Guo, R., & Zhang, R. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.348 · Cited by 8
Enzyme polymorphism in warfarin dose management after pediatric cardiac surgery
Najibi, B., Tabib, A., Dalili, M., Baghaei, R., & Poopak, B. (2015) · Research in Cardiovascular Medicine · doi:10.5812/cardiovascmed.27963v2 · Cited by 8
Henry, B. L., & Desai, U. R. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc182 · Cited by 8
Pregnancy managed by unfractionated heparin after mechanical aortic valve replacement
Kai, S., Fujita, Y., Sato, Y., Kido, S., Hidaka, N., Sakamoto, I., & Kato, K. (2018) · Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1512573 · Cited by 3
Zotova, I. V., Nikitin, A. G., Фаттахова, Э. Н., Бровкин, А. Н., Ходырев, Д. С., Лаврикова, Е. Ю., Юрьевна, И. М., Косухина, А. С., Носиков, В. В., & Zateyshchikov, D. A. (2013) · Journal of clinical practice · doi:10.17816/clinpract443-10 · Cited by 7
Iwai, C., Jo, T., Konishi, T., Kumazawa, R., Matsui, H., Fushimi, K., & Yasunaga, H. (2022) · Gerontology · doi:10.1159/000528606 · Cited by 7
Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype
Kwon, M., On, Y., Huh, W., Ko, J., Kim, D., Kim, J. S., & Lee, S. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.06.040 · Cited by 7
Genetic Polymorphism of Cytochrome P450 2C9 (CYP2C9) in Two Ethnic Groups in Iran
Ataby, O. A., Tabari, R. G., Mansourian, A. R., Samaei, N. M., & Marjani, A. (2013) · American Journal of Biomedical Sciences · doi:10.5099/aj130300177 · Cited by 7
Sychev, D. A., Antonov, I. M., Zagrebin, S. V., Gasanov, N. A., & Kukes, V. G. (2007) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2007-3-2-59-66 · Cited by 7
Huang, T., Zhang, L., He, Q., Li, Y.-B., Dai, Z.-L., Zheng, J., Cheng, P.-Q., & He, Y. (2017) · Australasian Physical & Engineering Sciences in Medicine · doi:10.1007/s13246-016-0519-x · Cited by 7
Gladding, P. A., Mackay, J., Zeng, I. S. L., Stewart, R., Prabkahar, R., Webster, M. W. I., & White, H. D. (2010) · Personalized Medicine · doi:10.2217/pme.10.24 · Cited by 7
Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype
Osman, A., Enström, C., & Lindahl, T. L. (2007) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e3280444bfd · Cited by 7
Sy, L. (2009) · PubMed · Cited by 7
Ichimura, Y., Takahashi, H., Lee, M. T. M., Shiomi, M., Mihara, K., Morita, T., Chen, Y.-T., & Echizen, H. (2012) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0009-6 · Cited by 6
Self-citationDietz, N., Ruff, C. T., Giugliano, R. P., Mercuri, M. F., & Antman, E. M. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.03.055 · Cited by 6
Liu, P., Liu, Z., Niu, M.-H., Chen, P., Shi, Y.-B., He, F., & Guo, R. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.803233 · Cited by 6
Pharmacogenetic Testing for Guiding de novo Phenprocoumon Therapy in Stroke Patients
Arnold, M.-L., Grond‐Ginsbach, C., Kloß, M., Mascio, M. T. D., Veltkamp, R. C., Ringleb, P. A., & Lichy, C. (2009) · Cerebrovascular Diseases · doi:10.1159/000235992 · Cited by 6
Genetic Variations and Their Influence on Risk and Treatment of Venous Thrombosis
Leitner, J. M., Mannhalter, C., & Jilma, B. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.4.423 · Cited by 6
Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China
Jin, T., Shi, X., Wang, L., Wang, H., Feng, T., & Kang, L. (2016) · BMC Genetics · doi:10.1186/s12863-016-0379-0 · Cited by 6
Hernández-Suárez, D. F., Claudio‐Campos, K., Mirabal-Arroyo, J. E., Torres-Hernández, B. A., López‐Candales, A., Melín, K., & Duconge-Soler, J. (2016) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709616682049 · Cited by 6
Hong, H., Zhang, W., Su, Z., Shen, J., Ge, W., Ning, B., Fang, H., Perkins, R., Shi, L. M., & Tong, W. (2013) · Springer eBooks · doi:10.1007/978-81-322-1184-6_3 · Cited by 7
Pharmacogenetics in Cardiovascular Diseases
Cavallari, L. H., & Momary, K. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00006-1 · Cited by 6
The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations
Sominsky, S., Korostishevsky, M., Kurnik, D., Aklillu, E., Cohen, Y., Ken‐Dror, G., Loebstein, R., Halkin, H., & Gak, E. (2014) · Journal of Applied Genetics · doi:10.1007/s13353-013-0189-2 · Cited by 6
No TGFBRII germline mutations in juvenile polyposis patients without SMAD4 or BMPR1A mutation
Brosens, L., van Hattem, W. V., Kools, M. C. E., Ezendam, C., Morsink, F., Leng, D. W. W., Giardiello, F., & Offerhaus, G. (2008) · Gut · doi:10.1136/gut.2008.161232 · Cited by 6
Shi, X., Wang, L., Du, S., Wang, H., Feng, T., Jin, T., & Kang, L. (2015) · Biomarkers · doi:10.3109/1354750x.2015.1068859 · Cited by 5
Effects of Teicoplanin on the PT-INR Controlled by Warfarin in Infection Patients
Nakano, T., Nakamura, T., Nakamura, Y., Irie, K., Sato, K., Matsuo, K., Imakyure, O., Ogata, K., 三島, 健., & Kamimura, H. (2017) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.17-00023 · Cited by 5
Yasaka, M., Brainsky, A., & Toyoda, Ḱ. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0428 · Cited by 5
Boonyawat, K., & Angchaisuksiri, P. (2022) · Hematology · doi:10.1182/hematology.2022000383 · Cited by 5
Pharmakogenetik und Pharmakogenomik
Roots, I., Laschinski, G., & Meyer, U. (2008) · Springer eBooks · doi:10.1007/978-3-540-69414-4_13 · Cited by 6
Lee, K., Woo, H. I., Bang, O. Y., On, Y., Kim, J. S., & Lee, S. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0219-1 · Cited by 5
Moon, H., Noh, J., Yun, Y., Kim, H. Y., Yun, I. J., Song, J., & Kim, J. Q. (2011) · PubMed · Cited by 5
Liew, C.-L., Yen, J.-H., Liu, A., & Liu, I. Y. (2013) · Tzu Chi Medical Journal · doi:10.1016/j.tcmj.2013.06.005 · Cited by 5
Multiple gene polymorphisms and warfarin sensitivity
Shikata, E., Ieiri, I., Ishiguro, S., Takane, H., Ohgi, S., & Otsubo, K. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0173-4 · Cited by 5
Self-citationAllabi, A. C., Horsmans, Y., Alvarez, J., Bigot, A. K., Verbeeck, R. K., Yaşar, Ü., & Gala, J. (2011) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-011-0056-7 · Cited by 5
Lee, S. (2009) · Gastroenterology Research · doi:10.4021/gr2009.04.1283 · Cited by 5
Madhan, S., Kumar, D. K., Kumar, D. T., Balachander, J., & Chandrasekaran, A. (2013) · Cited by 4
O’Brien, T. J., Fenton, K., Sidahmed, A., Barbour, A., & Harralson, A. F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111226 · Cited by 4
Pharmacogenetics of warfarin treatment for potential clinical application
Rieder, M. J. (2007) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-007-0069-6 · Cited by 4
Zhu, Z., He, J., Zeng, T., Qin, H., Xu, J., & Ren‐Heidenreich, L. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmu028 · Cited by 4
Nakagita, K., Wada, K., Mukai, Y., Uno, T., Nishino, R., Matsuda, S., Takenaka, H., Terakawa, N., Oita, A., & Takada, M. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2483-8 · Cited by 4
Wheeler, M. T., Ho, M. Y., Knowles, J. W., Pavlovic, A., & Ashley, E. A. (2008) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-007-9007-8 · Cited by 4
Chronic Antithrombotic Therapy in Post–Myocardial Infarction Patients
Nagarakanti, R., Sodhi, S. S., Lee, R. H., & Ezekowitz, M. D. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2007.12.017 · Cited by 4
Pharmacogenetics in Critical Care: Atrial Fibrillation as an Exemplar
Prows, C. A., & Beery, T. A. (2008) · Critical Care Nursing Clinics of North America · doi:10.1016/j.ccell.2008.01.006 · Cited by 4
Pharmacogenetics of Oral Anticoagulants
Jiménez‐Varo, E., Cañadas‐Garre, M., Aguilera, J., Callejas, D. G., Pérez-Ramírez, C., & Hernández, M. Á. C. (2013) · Springer eBooks · doi:10.1007/978-81-322-1184-6_21 · Cited by 4
Shifting Paradigms in the Pharmacogenetics of Warfarin
Gak, E., & Halkin, H. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.10.1373 · Cited by 4
Aoyama, T., Hirai, T., Tsuji, Y., Miyamoto, A., Itoh, T., Iwamoto, T., & Matsumoto, Y. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00778 · Cited by 3
Qian, M., Zhao, H., Lou, Y., Wang, J., Wang, S., Wang, Z., Ou, H., Li, J., Yang, F., Bai, L., et al. (2022) · Pharmacogenomics · doi:10.2217/pgs-2022-0038 · Cited by 3
Bryk, A. H., Wypasek, E., Awsiuk, M., Maj, D., & Undas, A. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6591-8 · Cited by 3
Suwanawiboon, B., Rotchanapanya, W., Mahaprom, K., Thongnoppakhun, W., Lalerd, Y., Limwongse, C., Sermsathanasawadi, N., & Owattanapanich, W. (2022) · Hematology · doi:10.1080/16078454.2021.2019891 · Cited by 3
Pharmacogenetics and Metabolism: Past, Present and Future
Rios-Santos, F., & Magno, L. A. V. (2012) · InTech eBooks · doi:10.5772/28154 · Cited by 3
Tratamiento de la trombosis venosa profunda iliofemoral y del síndrome postrombótico
Botella, F. G., Gómez, M. L., Portolés, O., & Gadea, L. I. (2013) · Angiología · doi:10.1016/j.angio.2013.05.005 · Cited by 3
Any effect of CYP2C9 variants on warfarin clearance in Chinese patients?
Zuo, Z., Lo, C. M. Y., Zhou, L., Yiu, H., Chau, C., Choi, K. C., Choi, D., Wong, R. S. M., Cheng, G. Y.-M., & You, J. H. S. (2007) · Thrombosis and Haemostasis · doi:10.1160/th06-04-0195 · Cited by 3
Nakamura, S., Watanabe, N., Yoshimura, N., Ozawa, S. W., Hirono, K., Ichida, F., & Taguchi, M. (2016) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2016.03.007 · Cited by 3
Effect of Oxycodone on the Prothrombin Time Controlled by Warfarin in Cancer Patients
Hosokawa, M., Habu, Y., Yano, I., Fukatsu, S., Kishimoto, N., Yokode, M., & Katsura, T. (2012) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.38.258 · Cited by 3
Warfarin doz ayarlanmasında genetik varyasyonların etkisi
Yüce, G. D. (2014) · Tuberkuloz ve Toraks · doi:10.5578/tt.7425 · Cited by 3
Kobayashi, S., Ishii, K., Yamada, Y. K., Ryu, E., Hashizume, J., Nose, S., Hara, T., Nakashima, M., & Ohyama, K. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1780-5 · Cited by 3
Akdeniz, C. S., Çevik, M., Canbolat, İ. P., Yurdakul, S., Çağatay, P., Çiftçi, Ç., Karaalp, A., & Duman, B. S. (2020) · Future Cardiology · doi:10.2217/fca-2020-0027 · Cited by 3
Sipeky, C., & Melegh, B. (2008) · Orvosi Hetilap · doi:10.1556/oh.2008.28456 · Cited by 3
Adult allogeneic haematopoietic stem cell transplantation: a single centre experience in Malaysia.
Gan, G. G., Zakaria, Z., Sangkar, J. V., Ar, H., Bee, P. C., Chin, E., & Teh, A. K. H. (2008) · PubMed · Cited by 3
Enhancing clinical research with pharmacogenomics: a practical perspective
Zhang, X. T., Blacutt, J., Lloyd, T. L., Mencer, M., Pratt, V., Kotha, J., Sheeran, L., & Adcock, S. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2481019 · Cited by 2
The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Eby, C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-283-4_8 · Cited by 2
Cho, E. H., Lee, K., Yang, M., Choi, R., Baek, S., Sohn, I., Kim, J. S., On, Y. K., Bang, O. Y., Cho, H.-J., et al. (2019) · Annals of Laboratory Medicine · doi:10.3343/alm.2020.40.3.216 · Cited by 2
Zhao, Z., Zhao, F., Wang, X., Liu, D., Liu, J., Zhang, Y., Hu, X. Y., Zhao, M., Tian, C., Dong, S., et al. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01258-y · Cited by 2
Saeki, M., Watanabe, A., Momo, K., Kashiwabara, Y., Iha, T., Nagata, T., Fujiwara, A., & Tanaka, K. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7762 · Cited by 2
Automation of diagnostic genetic testing: Mutation detection by cyclic minisequencing
Alagrund, K., & Orpana, A. (2013) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2013.857040 · Cited by 2
Individual (Personalized) Vulnerabilities
Pletcher, M. T., Cook, J. C., & Tassinari, M. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.01515-3 · Cited by 2
Zhuravleva, I. Y., Burkova, T. V., Rutkovskaya, N. V., Gorbunova, E. V., Odarenko, Y. N., Savostiyanova, Y. Y., & Goncharova, I. A. (2013) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2013-3-24-28 · Cited by 2
Pharmacogenomics in Clinical Care and Drug Discovery
Mendrinou, E., Κάτσιλα, Θ., Innocenti, F., Squassina, A., & Patrinos, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802971-8.00016-x · Cited by 2
Tamura, R., Watanabe, N., Nakamura, S., Yoshimura, N., Ozawa, S. W., Hirono, K., Ichida, F., & Taguchi, M. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02652-x · Cited by 2
Pharmacogenetics in Cardiovascular Diseases
Cavallari, L. H., & Momary, K. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391918-2.00005-6 · Cited by 2
Rad, F., Hamidpour, M., Dorgalaleh, A., & Poopak, B. (2018) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-018-0987-0 · Cited by 2
Single Nucleotide Polymorphisms in Molecular Diagnostics
Murugesan, G., Jang, S., & Jin-Yeong, H. (2012) · doi:10.1002/9781444398595.ch15 · Cited by 2
Loriot, M., & Beaune, P. H. (2007) · Personalized Medicine · doi:10.2217/17410541.4.4.413 · Cited by 2
Zhao, Y., Liu, N., Wang, Y., & Hickey, K. T. (2016) · Personalized Medicine · doi:10.2217/pme.15.41 · Cited by 1
Biological variables and their potential impact on biomarkers and precision medicine initiative
Halim, A. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816121-0.00008-8 · Cited by 1
Kawarada, Y., Miyazaki, M., Mitsuma, A., Ando, Y., & Ikesue, H. (2026) · International Cancer Conference Journal · doi:10.1007/s13691-026-00891-1 · Cited by 1
Warfarin Enantiomers Pharmacokinetics by CYP2C19
Akamine, Y., & Uno, T. (2012) · InTech eBooks · doi:10.5772/34752 · Cited by 1
Oh, S. (2013) · Journal of Korean Medical Association · doi:10.5124/jkma.2013.56.1.57 · Cited by 1
forecasting The largest prospective warfarin-treated cohort supports genetic
Holm, L., McGinnis, R. E., Rane, A., Deloukas, P., Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., & Ghori, M. J. R. (2012) · Cited by 1
Pranculis, A., & RanAelis, T. (2016) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000157 · Cited by 1
McMillin, G. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6164-9.00043-3 · Cited by 1
Metadata
- Authors
- Takahashi, H., Wilkinson, G. R., Nutescu, E. A., Morita, T., Ritchie, M. D., Scordo, M. G., Pengo, V., Barban, M., Padrini, R., Ieiri, I., Otsubo, K., Kashima, T., Kimura, S., Kijima, S., & Echizen, H.
- Affiliations
- Meiji Pharmaceutical University (JP)
- University of Illinois Chicago (US)
- Vanderbilt University (US)
- University of Messina (IT)
- University of Padua (IT)
- Tottori University (JP)
- Eisai (Japan) (JP)
- Corresponding author
- Takahashi, Harumi
- ORCID
- Venue
- Pharmacogenetics and Genomics
- Published
- 2006-02
- Volume
- 16
- Issue
- 2
- Pages
- 101-110
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2042292509
- Cited by
- 376
- References
- 31
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 10 · 2019: 17 · 2018: 9 · 2017: 14 · 2016: 16 · 2015: 16 · 2014: 28 · 2013: 25 · 2012: 25
- FWCI
- 38.09
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Pharmacogenetics and Genomics (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Funders
- Eisai
- National Institutes of Health (GM31304)
- U.S. Public Health Service
- National Institute of General Medical Sciences (GM31304, P01GM031304)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Keywords
- warfarin, VKORC1, CYP2C9, genetic polymorphism, vitamin K epoxide reductase, interpopulation variability, Japanese, Caucasians, African Americans, S-warfarin, anticoagulation, pharmacogenetics
- MeSH terms
- Aryl Hydrocarbon Hydroxylases, Black or African American, Female, Genotype, Humans, Mixed Function Oxygenases, Infant, Japan, Male, Pharmacogenetics, United States, Genetic Variation, Warfarin, Black People, White People, Asian People, Vitamin K Epoxide Reductases, Cytochrome P-450 CYP2C9
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
